Education
About Us
Working with TipRanks
Follow Us
CureVac (CVAC)
NASDAQ:CVAC
CVAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $5.28
Previous CloseN/A
Volume1.54M
Average Volume (3M)649.03K
Market Cap
$594.41M
Enterprise Value$92.14M
Total Cash (Recent Filing)-€60.63M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)4.9
Beta0.90
Next Earnings
Apr 10, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding224,305,680
10 Day Avg. Volume821,193
30 Day Avg. Volume649,027
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.25Price Target Upside240.07% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial OutlookCureVac ended with €550.9M in cash following GSK's payment of €400M for the revised COVID/flu agreement.
Patent RulingThe European Patent Office largely dismissed the patent opposition filed by BNTX challenging the validity of Curevac's foundational patent for split poly-A tail technology and confirmed its validity, subject to amendment.
Revenue PerformanceRevenue significantly surpassed expectations, driven by a new GSK license agreement and contributions from other collaborations.
Bears Say
Legal ChallengesNear-term focus remains on an intellectual property dispute with PFE/BNTX, indicating ongoing legal challenges.
Patient OutcomesMost patients progressed following the main treatment period.
Workforce ReductionA 30% workforce reduction is expected to complete by the end of the year as part of the company's restructuring efforts.
---
Ownership Overview
― Insiders
0.06% Mutual Funds
0.35% Other Institutional Investors
98.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CVAC FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was $2.21 and its highest was $5.28 in the past 12 months.
What is CureVac’s market cap?
CureVac’s market cap is $594.41M.
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Apr 10, 2025 which is today.
How were CureVac’s earnings last quarter?
CureVac released its earnings results on Nov 12, 2024. The company reported $1.664 earnings per share for the quarter, beating the consensus estimate of $1.554 by $0.11.
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate is -0.23.
How many shares outstanding does CureVac have?
CureVac has 224,305,680 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
CureVac reported an EPS of $1.664 in its last earnings report, beating expectations of $1.554. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is Platinum Investment Management. It holds CureVac’s shares valued at 0.
---
CureVac Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.25 (240.07% Upside)
$9.25 (240.07% Upside)
Blogger Sentiment
Neutral
CVAC Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $579.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.40%
12-Months-Change
Fundamentals
Return on Equity
17.08%
Trailing 12-Months
Asset Growth
6.87%
Trailing 12-Months
Company Description
CureVac
CureVac (CVAC) is a biotechnology company based in Germany that focuses on the development of therapies and vaccines utilizing messenger RNA (mRNA) technology. The company's core products are centered around the use of mRNA to stimulate the body's own production of proteins to combat various diseases, including cancer, infectious diseases, and rare diseases. CureVac is involved in both proprietary projects and collaborations with other pharmaceutical and biotech companies to advance its pipeline of innovative treatments.
---
CVAC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive trajectory for CureVac, with significant licensing deals, promising pipeline developments, and strategic cost reductions. However, ongoing litigation and certain financial impairments present challenges.Read More>---
CVAC Stock 12 Month Forecast
Average Price Target
$9.25
▲(240.07% Upside)
Technical Analysis
Best Analysts Covering CVAC
1 Year
1 Year Success Rate
2/26 ratings generated profit
1 Year Average Return
-36.81%
reiterated a buy rating 2 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -36.81% per trade.
---